Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Homology Medicines, Inc.    FIXX

HOMOLOGY MEDICINES, INC.

(FIXX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
15.67(c) 16.215(c) 14.8(c) 14.82(c) 14.24(c) Last
208 289 1 077 109 412 622 230 171 365 059 Volume
+0.32% +3.48% -8.73% +0.14% -3.91% Change
More quotes
Financials (USD)
Sales 2020 5,07 M - -
Net income 2020 -142 M - -
Net Debt 2020 - - -
P/E ratio 2020 -4,65x
Yield 2020 -
Sales 2021 3,70 M - -
Net income 2021 -155 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,11x
Yield 2021 -
Capitalization 644 M 644 M -
Capi. / Sales 2020 127x
Capi. / Sales 2021 174x
Nbr of Employees 195
Free-Float 94,6%
More Financials
Company
Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a... 
More about the company
Surperformance© ratings of Homology Medicines, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on HOMOLOGY MEDICINES, INC.
05/26HOMOLOGY MEDICINES : Announces Peer-Reviewed Publication Describing Molecular Ch..
AQ
05/12HOMOLOGY MEDICINES : 05/12/2020 Homology Medicines Announces Presentations on it..
PU
05/12Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Ge..
GL
05/08HOMOLOGY MEDICINES : 1Q Earnings Snapshot
AQ
05/07HOMOLOGY MEDICINES : 05/07/2020 Homology Medicines Reports First Quarter 2020 Fi..
PU
05/07HOMOLOGY MEDICINES : Management's Discussion and Analysis of Financial Condition..
AQ
05/07Homology Medicines Reports First Quarter 2020 Financial Results and Recent Hi..
GL
04/29HOMOLOGY MEDICINES : 04/29/2020 Homology Medicines Announces Presentations at Up..
PU
04/29Homology Medicines Announces Presentations at Upcoming American Society for G..
GL
03/16Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigati..
GL
03/12HOMOLOGY MEDICINES : 03/12/2020 Homology Medicines Reports Fourth Quarter and Fu..
PU
03/12HOMOLOGY MEDICINES : 4Q Earnings Snapshot
AQ
03/12Homology Medicines Reports Fourth Quarter and Full Year 2019 Financial Result..
GL
03/12HOMOLOGY MEDICINES : Management's Discussion and Analysis of Financial Condition..
AQ
02/20Homology Medicines to Participate in Upcoming Investor and Scientific Confere..
GL
More news
News in other languages on HOMOLOGY MEDICINES, INC.
05/26HOMOLOGY MEDICINES : Announces Peer-Reviewed Publication Describing Molecular Ch..
05/12HOMOLOGY MEDICINES : 05/12/2020 Homology Medicines Announces Presentations on it..
05/12Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Ge..
05/08HOMOLOGY MEDICINES : 1Q Earnings Snapshot
05/07HOMOLOGY MEDICINES : 05/07/2020 Homology Medicines Reports First Quarter 2020 Fi..
More news
Chart HOMOLOGY MEDICINES, INC.
Duration : Period :
Homology Medicines, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOMOLOGY MEDICINES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 32,50 $
Last Close Price 14,24 $
Spread / Highest target 160%
Spread / Average Target 128%
Spread / Lowest Target 68,5%
EPS Revisions
Managers
NameTitle
Arthur O. Tzianabos President, Chief Executive Officer & Director
Kush M. Parmar Chairman
W. Bradford Smith Chief Financial Officer, Secretary & Treasurer
Albert Seymour Chief Scientific Officer
Timothy P. Kelly Chief Technical Operations Officer
Sector and Competitors
1st jan.Capitalization (M$)
HOMOLOGY MEDICINES, INC.-31.21%644
GILEAD SCIENCES19.78%97 628
VERTEX PHARMACEUTICALS31.52%74 661
REGENERON PHARMACEUTICALS63.21%62 233
WUXI APPTEC CO., LTD.15.61%24 620
GENMAB A/S39.05%20 072